Janux Therapeutics, Inc. JANX

Rank #2189 · Nasdaq · $1.1B market cap

⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

29.9

P/E

-18.3

P/B

3.32

ROE

-18.2%

Op. Margin

-902.9%

Debt Ratio

12%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Weak

P/E -18.3x, P/B 3.32x. Ranks in the top 67% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -18.2%. Ranks in the top 88% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 12%. Ranks in the top 10% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆

Weak

Revenue decline of 6.1% year over year. Ranks in the top 78% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2021	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-116
2022	$0.0B	$-0.0B	$-0.0B	$-0.0B	-905.4	-92
2023	$0.0B	$-0.1B	$-0.1B	$0.4B	-779.0	12
2024	$0.0B	$-0.1B	$-0.1B	$0.4B	-779.0	10
2025	$0.0B	$-0.1B	$-0.1B	$0.3B	-902.9	12

← See the full screener